{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:47:50Z","timestamp":1794293270895,"version":"4.9.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The diagnosis of Parkinson\u2019s disease (PD) is currently based on clinical criteria, centered on the characteristic motor syndrome. However, motor manifestations become evident only after a significant proportion of nigro-striatal dopaminergic neurons have already undergone neurodegeneration. The recent \u201c\n                    <jats:italic>NSD-ISS<\/jats:italic>\n                    \u201d and \u201c\n                    <jats:italic>SynNeurGe<\/jats:italic>\n                    \u201d research frameworks have proposed new biological diagnostic criteria focusing on \u03b1-synucleinopathy, neurodegeneration, and genetic biomarkers, independent of clinical manifestations. These proposals intend to detect the disease at a \u201cbiologically early phase\u201d to foster advances in research and development of disease-modifying treatments. While the shift to a biological approach is mandatory to better understand PD, challenges to the new frameworks remain, including inherent criticisms, limitations in explaining PD clinical-biological complexity, restricted clinical applicability and related ethical concerns. In this paper, we describe the historical path toward the two biological proposals, explore critical issues and knowledge gaps emerging from them, and discuss the risk of their premature application in the clinical setting.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08076-z","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:11:23Z","timestamp":1762521083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Are we ready for a biological diagnosis of Parkinson\u2019s Disease?"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-565X","authenticated-orcid":false,"given":"Angelo Tiziano","family":"Cimmino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2413-1788","authenticated-orcid":false,"given":"Giulia","family":"Di Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-594X","authenticated-orcid":false,"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Bentivoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-5509","authenticated-orcid":false,"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"8076_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/MDS.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2015;30:1591\u2013601. https:\/\/doi.org\/10.1002\/MDS.26424.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/ARCHNEUR.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, et al. Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Archives Neurol. 2006;63:584\u20138. https:\/\/doi.org\/10.1001\/ARCHNEUR.63.4.584.","journal-title":"Archives Neurol"},{"key":"8076_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23:178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"key":"8076_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23:191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0.","journal-title":"Lancet Neurol"},{"key":"8076_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/JNNP.51.6.745","volume":"51","author":"WRG Gibb","year":"1988","unstructured":"Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg psychiatry. 1988;51:745\u201352. https:\/\/doi.org\/10.1136\/JNNP.51.6.745.","journal-title":"J Neurol Neurosurg psychiatry"},{"key":"8076_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/ARCHNEUR.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Archives Neurol. 1999;56:33\u201339. https:\/\/doi.org\/10.1001\/ARCHNEUR.56.1.33.","journal-title":"Archives Neurol"},{"key":"8076_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/MDS.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement disorders society scientific issues committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord Off J Mov Disord Soc. 2003;18:467\u201386. https:\/\/doi.org\/10.1002\/MDS.10459.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR8","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1002\/ANA.410320721","volume":"32","author":"DB Calne","year":"1992","unstructured":"Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson\u2019s disease. Annals Neurol. 1992;32:S125\u20137. https:\/\/doi.org\/10.1002\/ANA.410320721.","journal-title":"Annals Neurol"},{"key":"8076_CR9","doi-asserted-by":"crossref","unstructured":"Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci. 1817;4:223\u221236.","DOI":"10.1176\/appi.neuropsych.14.2.223"},{"key":"8076_CR10","doi-asserted-by":"publisher","unstructured":"Kulcsarova K, Skorvanek M, Postuma RB, Berg D. Defining Parkinson\u2019s disease: past and future. J Parkinson\u2019s Dis. 2024;14:S257\u221271. https:\/\/doi.org\/10.3233\/JPD-230411.","DOI":"10.3233\/JPD-230411"},{"key":"8076_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","volume":"5","author":"E Tolosa","year":"2006","unstructured":"Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson\u2019s disease. Lancet Neurol. 2006;5:75\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(05)70285-4.","journal-title":"Lancet Neurol"},{"key":"8076_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/MDS.25844","volume":"29","author":"D Berg","year":"2014","unstructured":"Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to redefine PD? introductory statement of the MDS task force on the definition of Parkinson\u2019s disease. Movement Disord Off J Mov Disord Soc. 2014;29:454\u201362. https:\/\/doi.org\/10.1002\/MDS.25844.","journal-title":"Movement Disord Off J Mov Disord Soc"},{"key":"8076_CR13","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 2009;8:1150\u20137. https:\/\/doi.org\/10.1016\/S1474-4422(09)70238-8.","journal-title":"Lancet Neurol"},{"key":"8076_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1474-4422(13)70047-4","volume":"12","author":"D Berg","year":"2013","unstructured":"Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, et al. Changing the research criteria for the diagnosis of Parkinson\u2019s disease: obstacles and opportunities. Lancet Neurol. 2013;12:514\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(13)70047-4.","journal-title":"Lancet Neurol"},{"key":"8076_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340. https:\/\/doi.org\/10.1038\/42166.","journal-title":"Nature"},{"key":"8076_CR16","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/BRAIN\/AWAD150","volume":"146","author":"P Calabresi","year":"2023","unstructured":"Calabresi P. Di Lazzaro G, Marino G, Campanelli F, Ghiglieri V. Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease. Brain J Neurol. 2023;146:3587\u201397. https:\/\/doi.org\/10.1093\/BRAIN\/AWAD150.","journal-title":"Brain J Neurol"},{"key":"8076_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/J.EXPNEUROL.2007.08.006","volume":"209","author":"MF Chesselet","year":"2008","unstructured":"Chesselet MF. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson\u2019s disease. ExpNeurol. 2008;209:22\u201327. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2007.08.006.","journal-title":"ExpNeurol"},{"key":"8076_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/JNC.13627","volume":"139","author":"LA Volpicelli-Daley","year":"2016","unstructured":"Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS. How can rAAV-\u03b1-synuclein and the fibril \u03b1-synuclein models advance our understanding of Parkinson\u2019s disease?. J Neurochem. 2016;139:131\u201355. https:\/\/doi.org\/10.1111\/JNC.13627.","journal-title":"J Neurochem"},{"key":"8076_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/SCIENCE.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson\u2019s disease. Science (N. Y, N. Y). 2003;302:841 https:\/\/doi.org\/10.1126\/SCIENCE.1090278.","journal-title":"Science (N. Y, N. Y)"},{"key":"8076_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/J.1468-1331.2009.02900.X","volume":"17","author":"P Barone","year":"2010","unstructured":"Barone P. Neurotransmission in Parkinson\u2019s disease: beyond dopamine. Eur J Neurol. 2010;17:364\u201376. https:\/\/doi.org\/10.1111\/J.1468-1331.2009.02900.X.","journal-title":"Eur J Neurol"},{"key":"8076_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/MDS.24962","volume":"27","author":"M Poulopoulos","year":"2012","unstructured":"Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2012;27:831\u201342. https:\/\/doi.org\/10.1002\/MDS.24962.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR22","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/MDS.27193","volume":"32","author":"SA Schneider","year":"2017","unstructured":"Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord Off J Mov Disord Soc. 2017;32:1504\u201323. https:\/\/doi.org\/10.1002\/MDS.27193.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22:407\u201317. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6.","journal-title":"Lancet Neurol"},{"key":"8076_CR24","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1212\/WNL.0B013E318278FE32","volume":"79","author":"JM Milber","year":"2012","unstructured":"Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79:2307\u201314. https:\/\/doi.org\/10.1212\/WNL.0B013E318278FE32.","journal-title":"Neurology"},{"key":"8076_CR25","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/J.PARKRELDIS.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018;46:S30\u2013S33. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2017.07.033.","journal-title":"Parkinsonism Relat Disord"},{"key":"8076_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/NEN.0B013E3181AC10A7","volume":"68","author":"WR Markesbery","year":"2009","unstructured":"Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol. 2009;68:816\u201322. https:\/\/doi.org\/10.1097\/NEN.0B013E3181AC10A7.","journal-title":"J Neuropathol Exp Neurol"},{"key":"8076_CR27","doi-asserted-by":"publisher","unstructured":"Koeglsperger T, Rumpf SL, Schlie\u00dfer P, Struebing FL, Brendel M, Levin J, et al. Neuropathology of incidental Lewy body & prodromal Parkinson\u2019s disease. Mol Neurodegen. 2023;18:32. https:\/\/doi.org\/10.1186\/S13024-023-00622-7.","DOI":"10.1186\/S13024-023-00622-7"},{"key":"8076_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","volume":"88","author":"AJ Thomas","year":"2017","unstructured":"Thomas AJ, Attems J, Colloby SJ, O\u2019Brien JT, Mckeith I, Walker R, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology. 2017;88:276\u201383. https:\/\/doi.org\/10.1212\/WNL.0000000000003512.","journal-title":"Neurology"},{"key":"8076_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/B978-0-323-85555-6.00001-1","volume":"193","author":"K Ezzat","year":"2023","unstructured":"Ezzat K, Sturchio A, Espay AJ. The shift to a proteinopenia paradigm in neurodegeneration. Handbook Clin Neurol. 2023;193:23\u201332. https:\/\/doi.org\/10.1016\/B978-0-323-85555-6.00001-1.","journal-title":"Handbook Clin Neurol"},{"key":"8076_CR30","doi-asserted-by":"publisher","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176. https:\/\/doi.org\/10.1038\/S41419-023-05672-9.","DOI":"10.1038\/S41419-023-05672-9"},{"key":"8076_CR31","doi-asserted-by":"publisher","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K, et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease. Acta Neuropathol Commun. 2022;10:133. https:\/\/doi.org\/10.1186\/S40478-022-01440-6.","DOI":"10.1186\/S40478-022-01440-6"},{"key":"8076_CR32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/MDS.26620","volume":"31","author":"T Schirinzi","year":"2016","unstructured":"Schirinzi T, Madeo G, Martella G, Maltese M, Picconi B, Calabresi P, et al. Early synaptic dysfunction in Parkinson\u2019s disease: insights from animal models. Mov Disord. 2016;31:802\u201313. https:\/\/doi.org\/10.1002\/MDS.26620.","journal-title":"Mov Disord"},{"key":"8076_CR33","doi-asserted-by":"publisher","unstructured":"Ghiglieri V, Calabrese V, Calabresi P. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol. 2018;9:295. https:\/\/doi.org\/10.3389\/FNEUR.2018.00295.","DOI":"10.3389\/FNEUR.2018.00295"},{"key":"8076_CR34","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson\u2019s disease. Movement Disord. 2015;30:1600\u201311. https:\/\/doi.org\/10.1002\/mds.26431.","journal-title":"Movement Disord"},{"key":"8076_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/S41582-024-00950-2","volume":"20","author":"N Hattori","year":"2024","unstructured":"Hattori N. Towards the era of biological biomarkers for Parkinson disease. Nat Rev Neurol. 2024;20:317\u20138. https:\/\/doi.org\/10.1038\/S41582-024-00950-2.","journal-title":"Nat Rev Neurol"},{"key":"8076_CR36","doi-asserted-by":"publisher","unstructured":"Zarkali A, Thomas GEC, Zetterberg H, Weil RS. Neuroimaging and fluid biomarkers in Parkinson\u2019s disease in an era of targeted interventions. Nat commun. 2024;15:5661. https:\/\/doi.org\/10.1038\/S41467-024-49949-9.","DOI":"10.1038\/S41467-024-49949-9"},{"key":"8076_CR37","doi-asserted-by":"publisher","unstructured":"Jia F, Fellner A, Kumar KR. Monogenic Parkinson's disease: genotype, phenotype, pathophysiology, and genetic testing. Genes. 2022;13:471. https:\/\/doi.org\/10.3390\/GENES13030471.","DOI":"10.3390\/GENES13030471"},{"key":"8076_CR38","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, et al. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA. 2024;331:1298\u2013306. https:\/\/doi.org\/10.1001\/jama.2024.0792.","journal-title":"JAMA"},{"key":"8076_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 2019;18:573\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(19)30024-9.","journal-title":"Lancet Neurol"},{"key":"8076_CR40","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ACN3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Annal Clin Transl Neurol. 2016;3:812\u20138. https:\/\/doi.org\/10.1002\/ACN3.338.","journal-title":"Annal Clin Transl Neurol"},{"key":"8076_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/J.JALZ.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/J.JALZ.2018.02.018.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"8076_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(23)00456-8","volume":"23","author":"CR Jack","year":"2024","unstructured":"Jack CR. Criteria for a biological definition of neuronal \u03b1-synuclein disease-a major conceptual step forward. Lancet Neurol. 2024;23:129\u201330. https:\/\/doi.org\/10.1016\/S1474-4422(23)00456-8.","journal-title":"Lancet Neurol"},{"key":"8076_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1474-4422(23)00503-3","volume":"23","author":"SKL Darweesh","year":"2024","unstructured":"Darweesh SKL, Sampaio C, Bloem BR. Has the time come to redefine Parkinson\u2019s disease. Lancet Neurol. 2024;23:130\u20133. https:\/\/doi.org\/10.1016\/S1474-4422(23)00503-3.","journal-title":"Lancet Neurol"},{"key":"8076_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1474-4422(23)00512-4","volume":"23","author":"JA Obeso","year":"2024","unstructured":"Obeso JA, Calabresi P. Parkinson\u2019s disease is a recognisable and useful diagnostic entity. Lancet Neurol. 2024;23:133\u20134. https:\/\/doi.org\/10.1016\/S1474-4422(23)00512-4.","journal-title":"Lancet Neurol"},{"key":"8076_CR45","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1474-4422(24)00225-4","volume":"23","author":"JG Goldman","year":"2024","unstructured":"Goldman JG, Boeve BF, Galasko D, Galvin JE, Leverenz JB, Taylor JP. Concerns with the new biological research criteria for synucleinopathy. Lancet Neurol. 2024;23:660\u20131. https:\/\/doi.org\/10.1016\/S1474-4422(24)00225-4.","journal-title":"Lancet Neurol"},{"key":"8076_CR46","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1474-4422(24)00217-5","volume":"23","author":"FB Ketchum","year":"2024","unstructured":"Ketchum FB, Chin NA. Concerns with the new biological research criteria for synucleinopathy. Lancet Neurol. 2024;23:659 https:\/\/doi.org\/10.1016\/S1474-4422(24)00217-5.","journal-title":"Lancet Neurol"},{"key":"8076_CR47","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1474-4422(24)00213-8","volume":"23","author":"BF Boeve","year":"2024","unstructured":"Boeve BF, Davis AA, Ju YE, Kantarci K, Singer W, Videnovic A, et al. Concerns with the new biological research criteria for synucleinopathy. Lancet Neurol. 2024;23:659\u201360. https:\/\/doi.org\/10.1016\/S1474-4422(24)00213-8.","journal-title":"Lancet Neurol"},{"key":"8076_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/MDS.30173","volume":"40","author":"TA Mestre","year":"2025","unstructured":"Mestre TA, Sampaio C. Is Parkinson disease better defined solely by biology or as a clinical\u2013biological entity? Lessons to be learned from alzheimer\u2019s disease on biological definition and staging. Mov Disord. 2025;40:625\u20136. https:\/\/doi.org\/10.1002\/MDS.30173.","journal-title":"Mov Disord"},{"key":"8076_CR49","doi-asserted-by":"publisher","unstructured":"Cardoso F, Schmidt P. Proposed biological definitions of Parkinson\u2019s disease confuse understanding without delivering meaningful advances. J Parkinson\u2019s Dis. 2025;15:939\u2212943. https:\/\/doi.org\/10.1177\/1877718X241308482,.","DOI":"10.1177\/1877718X241308482"},{"key":"8076_CR50","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/MDS.30007","volume":"39","author":"LV Kalia","year":"2024","unstructured":"Kalia LV, Berg D, Kordower JH, Shannon KM, Taylor JP, Cardoso F, et al. International Parkinson and movement disorder society viewpoint on biological frameworks of parkinson\u2019s disease: current status and future directions. Mov Disord. 2024;39:1710\u20135. https:\/\/doi.org\/10.1002\/MDS.30007.","journal-title":"Mov Disord"},{"key":"8076_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/JAMANEUROL.2017.0985","volume":"74","author":"D Jennings","year":"2017","unstructured":"Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Conversion to parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 2017;74:933\u201340. https:\/\/doi.org\/10.1001\/JAMANEUROL.2017.0985.","journal-title":"JAMA Neurol"},{"key":"8076_CR52","first-page":"S63","volume":"38","author":"K Marek","year":"2023","unstructured":"Marek K, Russell D, Concha L, Caspell-Garcia C, Brown E, Brumm M. et al. Widespread synuclein pathology in hyposmicsprecedes dopamine transporter deficit in PARS. Mov Disord. 2023;38:S63\u2013S139.","journal-title":"Mov Disord"},{"key":"8076_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20:203\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(20)30449-X.","journal-title":"Lancet Neurol"},{"key":"8076_CR54","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1192\/BJP.2020.234","volume":"218","author":"G Roberts","year":"2021","unstructured":"Roberts G, Donaghy PC, Lloyd J, Durcan R, Petrides G, Colloby SJ, et al. Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. Br J Psychiatry: J Ment Sci. 2021;218:276\u201382. https:\/\/doi.org\/10.1192\/BJP.2020.234.","journal-title":"Br J Psychiatry: J Ment Sci"},{"key":"8076_CR55","doi-asserted-by":"publisher","unstructured":"Coughlin DG, Macleod KR, Middleton JS, Bozoki AC, Galvin JE, Irwin DJ, et al. Association of CSF \u03b1-Synuclein Seeding Amplification Assay Results with Clinical Features of Possible and Probable Dementia with Lewy Bodies. Neurology. 2024;103:e209656. https:\/\/doi.org\/10.1212\/WNL.0000000000209656,.","DOI":"10.1212\/WNL.0000000000209656"},{"key":"8076_CR56","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","volume":"92","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019;92:329\u201337. https:\/\/doi.org\/10.1212\/WNL.0000000000006926.","journal-title":"Neurology"},{"key":"8076_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/BRAIN\/AWAD388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu Y, Hirst WD, Federoff HJ, Harms AS, Stoessl AJ, Kordower JH. Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain A J Neurol. 2024;147:444\u201357. https:\/\/doi.org\/10.1093\/BRAIN\/AWAD388.","journal-title":"Brain A J Neurol"},{"key":"8076_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-211-45295-0_16","volume":"70","author":"GM Halliday","year":"2006","unstructured":"Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson\u2019s disease. Journal of neural transmission. Supplementum. 2006;70:99\u2013103. https:\/\/doi.org\/10.1007\/978-3-211-45295-0_16.","journal-title":"Supplementum"},{"key":"8076_CR59","doi-asserted-by":"publisher","unstructured":"Bendetowicz D, Planche V, Bezard E, Dehay B, Meissner WG. Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease. J Parkinson\u2019s Dis. 2025;15:944\u2212952. https:\/\/doi.org\/10.1177\/1877718X241313443.","DOI":"10.1177\/1877718X241313443"},{"key":"8076_CR60","doi-asserted-by":"publisher","unstructured":"Espay AJ, Lees AJ, Cardoso F, Frucht SJ, Erskine D, Sandoval IM, et al. The \u03b1-synuclein seed amplification assay: interpreting a test of Parkinson\u2019s pathology. Parkinsonism Related Dis. 2025;131:107256. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107256.","DOI":"10.1016\/j.parkreldis.2024.107256"},{"key":"8076_CR61","doi-asserted-by":"publisher","unstructured":"Mulroy E, Erro R, Bhatia KP, Hallett M. Refining the clinical diagnosis of Parkinson\u2019s disease. Parkinsonism Related Dis. 2024;122. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106041.","DOI":"10.1016\/j.parkreldis.2024.106041"},{"key":"8076_CR62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/JNEN\/62.4.389","volume":"62","author":"T Ishizawa","year":"2003","unstructured":"Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. Journal Neuropathol Exp Neurol. 2003;62:389\u201397. https:\/\/doi.org\/10.1093\/JNEN\/62.4.389.","journal-title":"Journal Neuropathol Exp Neurol"},{"key":"8076_CR63","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/NG.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nature Genet. 2014;46:989\u201393. https:\/\/doi.org\/10.1038\/NG.3043.","journal-title":"Nature Genet"},{"key":"8076_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/J.1469-1809.2009.00560.X","volume":"74","author":"TL Edwards","year":"2010","unstructured":"Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Annals Hum Genet. 2010;74:97\u2013109. https:\/\/doi.org\/10.1111\/J.1469-1809.2009.00560.X.","journal-title":"Annals Hum Genet"},{"key":"8076_CR65","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/MDC3.14068","volume":"11","author":"LM Jackson","year":"2024","unstructured":"Jackson LM, Woodruff BK, Tremblay C, Shill HA, Beach TG, Serrano GE, et al. Parkinson\u2019s disease associated with G2019S LRRK2 mutations without Lewy body pathology. Mov Disord Clin Pract. 2024;11:874\u20138. https:\/\/doi.org\/10.1002\/MDC3.14068.","journal-title":"Mov Disord Clin Pract"},{"key":"8076_CR66","doi-asserted-by":"publisher","unstructured":"Henderson MX, Sengupta M, Trojanowski JQ, Lee VMY. Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease. Acta Neuropathologica Commun. 2019;7:183. https:\/\/doi.org\/10.1186\/S40478-019-0836-X.","DOI":"10.1186\/S40478-019-0836-X"},{"key":"8076_CR67","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.expneurol.2004.01.007","volume":"187","author":"PT Kotzbauer","year":"2004","unstructured":"Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, et al. Fibrillization of \u03b1-synuclein and tau in familial Parkinson\u2019s disease caused by the A53T \u03b1-synuclein mutation. Exp Neurol. 2004;187:279\u201388. https:\/\/doi.org\/10.1016\/j.expneurol.2004.01.007.","journal-title":"Exp Neurol"},{"key":"8076_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/S00401-002-0563-3","volume":"104","author":"JE Duda","year":"2002","unstructured":"Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VMY, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002;104:7\u201311. https:\/\/doi.org\/10.1007\/S00401-002-0563-3.","journal-title":"Acta Neuropathol"},{"key":"8076_CR69","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ANA.25179","volume":"83","author":"Y Chu","year":"2018","unstructured":"Chu Y, Buchman AS, Olanow CW, Kordower JH. Do subjects with minimal motor features have prodromal Parkinson disease. Annal Neurol. 2018;83:562\u201374. https:\/\/doi.org\/10.1002\/ANA.25179.","journal-title":"Annal Neurol"},{"key":"8076_CR70","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/BRAIN\/AWAC171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan L, Li C, Meng L, Tian Y, He M, Yuan X, et al. Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain A J Neurol. 2022;145:3454\u201371. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC171.","journal-title":"Brain A J Neurol"},{"key":"8076_CR71","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/BRAIN\/AWAE002","volume":"147","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Lees AJ. Are we entering the \u2018Tau-lemaic\u2019 era of Parkinson\u2019s disease?. Brain A J Neurol. 2024;147:330\u20132. https:\/\/doi.org\/10.1093\/BRAIN\/AWAE002.","journal-title":"Brain A J Neurol"},{"key":"8076_CR72","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/JNC.15257","volume":"157","author":"F Hadi","year":"2021","unstructured":"Hadi F, Akrami H, Totonchi M, Barzegar A, Nabavi SM, Shahpasand K. \u03b1-synuclein abnormalities trigger focal tau pathology, spreading to various brain areas in Parkinson disease. J Neurochem. 2021;157:727\u201351. https:\/\/doi.org\/10.1111\/JNC.15257.","journal-title":"J Neurochem"},{"key":"8076_CR73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/S11910-022-01207-5","volume":"22","author":"G Arena","year":"2022","unstructured":"Arena G, Sharma K, Agyeah G, Kr\u00fcger R, Gr\u00fcnewald A, Fitzgerald JC. Neurodegeneration and Neuroinflammation in Parkinson\u2019s disease: a Self-Sustained Loop. Curr Neurol Neurosci Rep. 2022;22:427\u201340. https:\/\/doi.org\/10.1007\/S11910-022-01207-5.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"8076_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/MDS.28075","volume":"36","author":"EC Hirsch","year":"2021","unstructured":"Hirsch EC, Standaert DG. Ten unsolved questions about neuroinflammation in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2021;36:16\u201324. https:\/\/doi.org\/10.1002\/MDS.28075.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR75","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ANA.25557","volume":"86","author":"V Grozdanov","year":"2019","unstructured":"Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, et al. Increased immune activation by pathologic \u03b1-synuclein in Parkinson\u2019s disease. Annal Neurol. 2019;86:593\u2013606. https:\/\/doi.org\/10.1002\/ANA.25557.","journal-title":"Annal Neurol"},{"key":"8076_CR76","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"D Sulzer","year":"2017","unstructured":"Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides. Nature. 2017;546:656\u201361. https:\/\/doi.org\/10.1038\/nature22815.","journal-title":"Nature"},{"key":"8076_CR77","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/S00401-019-01974-5","volume":"137","author":"X Li","year":"2019","unstructured":"Li X, Koudstaal W, Fletcher L, Costa M, van Winsen M, Siregar B, et al. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology. Acta Neuropathol. 2019;137:825\u201336. https:\/\/doi.org\/10.1007\/S00401-019-01974-5.","journal-title":"Acta Neuropathol"},{"key":"8076_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21228421","volume":"21","author":"C Marogianni","year":"2020","unstructured":"Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D. Xiromerisiou G. Neurodegeneration and inflammation-an interesting Interplay in Parkinson\u2019s disease. Int J Mol Sci. 2020;21:1\u201315. https:\/\/doi.org\/10.3390\/IJMS21228421.","journal-title":"Int J Mol Sci"},{"key":"8076_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.CELLIMM.2018.02.011","volume":"327","author":"MN Karpenko","year":"2018","unstructured":"Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM, Bernadotte A. Interleukin-1\u03b2, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-\u03b1 levels in CSF and serum in relation to the clinical diversity of Parkinson\u2019s disease. Cell Immunol. 2018;327:77\u201382. https:\/\/doi.org\/10.1016\/J.CELLIMM.2018.02.011.","journal-title":"Cell Immunol"},{"key":"8076_CR80","doi-asserted-by":"publisher","unstructured":"Di Lazzaro G, Picca A, Boldrini S, Bove F, Marzetti E, Petracca M, et al. Differential profiles of serum cytokines in Parkinson\u2019s disease according to disease duration. Neurobiol Dis. 2024;190:106371. https:\/\/doi.org\/10.1016\/J.NBD.2023.106371.","DOI":"10.1016\/J.NBD.2023.106371"},{"key":"8076_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JPD-230154","volume":"14","author":"L Walker","year":"2024","unstructured":"Walker L, Attems J. Prevalence of concomitant pathologies in parkinson\u2019s disease: implications for prognosis, diagnosis, and insights into common pathogenic mechanisms. J Parkinson\u2019s Dis. 2024;14:35. https:\/\/doi.org\/10.3233\/JPD-230154.","journal-title":"J Parkinson\u2019s Dis"},{"key":"8076_CR82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/B978-0-323-85538-9.00012-2","volume":"192","author":"Y Chu","year":"2023","unstructured":"Chu Y, Hirst WD, Kordower JH. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handbook Clin Neurol. 2023;192:57\u201371. https:\/\/doi.org\/10.1016\/B978-0-323-85538-9.00012-2.","journal-title":"Handbook Clin Neurol"},{"key":"8076_CR83","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/BRAIN\/AWAD059","volume":"146","author":"JL Robinson","year":"2023","unstructured":"Robinson JL, Xie SX, Baer DR, Suh ER, Van Deerlin VM, Loh NJ, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain A J Neurol. 2023;146:2557\u201369. https:\/\/doi.org\/10.1093\/BRAIN\/AWAD059.","journal-title":"Brain A J Neurol"},{"key":"8076_CR84","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/J.PARKRELDIS.2014.02.012","volume":"20","author":"BN Dugger","year":"2014","unstructured":"Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord. 2014;20:525\u20139. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2014.02.012.","journal-title":"Parkinsonism Relat Disord"},{"key":"8076_CR85","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/ALZ.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, et al. Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2024;20:2444\u201352. https:\/\/doi.org\/10.1002\/ALZ.13658.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"8076_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-9-43","volume":"9","author":"S Moussaud","year":"2014","unstructured":"Moussaud S, Jones DR, Moussaud-Lamodi\u00e8re EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration. Mol Neurodegeneration. 2014;9:43. https:\/\/doi.org\/10.1186\/1750-1326-9-43.","journal-title":"Mol Neurodegeneration"},{"key":"8076_CR87","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/S41583-021-00542-9","volume":"23","author":"J Blesa","year":"2022","unstructured":"Blesa J, Foffani G, Dehay B, Bezard E, Obeso JA. Motor and non-motor circuit disturbances in early Parkinson disease: which happens first. Nat Rev Neurosci. 2022;23:115\u201328. https:\/\/doi.org\/10.1038\/S41583-021-00542-9.","journal-title":"Nat Rev Neurosci"},{"key":"8076_CR88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/S41582-023-00905-Z","volume":"20","author":"S Citro","year":"2024","unstructured":"Citro S, Di Lazzaro G, Cimmino AT, Giuffr\u00e8 GM, Marra C, Calabresi P. A multiple hits hypothesis for memory dysfunction in Parkinson disease. Nat Rev Neurol. 2024;20:50\u201361. https:\/\/doi.org\/10.1038\/S41582-023-00905-Z.","journal-title":"Nat Rev Neurol"},{"key":"8076_CR89","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/J.BBR.2014.07.037","volume":"277","author":"M Politis","year":"2015","unstructured":"Politis M, Niccolini F. Serotonin in Parkinson\u2019s disease. Behav Brain Res. 2015;277:136\u201345. https:\/\/doi.org\/10.1016\/J.BBR.2014.07.037.","journal-title":"Behav Brain Res"},{"key":"8076_CR90","doi-asserted-by":"publisher","unstructured":"Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C. The noradrenergic system in parkinson\u2019s disease. Front Pharmacol. 2020;11:435. https:\/\/doi.org\/10.3389\/FPHAR.2020.00435.","DOI":"10.3389\/FPHAR.2020.00435"},{"key":"8076_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/BRAIN\/AWX310","volume":"141","author":"NJ Ray","year":"2018","unstructured":"Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kountouriotis GK, et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson\u2019s disease. Brain: a J Neurol. 2018;141:165\u201376. https:\/\/doi.org\/10.1093\/BRAIN\/AWX310.","journal-title":"Brain: a J Neurol"},{"key":"8076_CR92","unstructured":"Charcot JM, Vulpian A. De la paralysie agitante. Rafael Gonzalez Maldonado; 1862. pp 86."},{"key":"8076_CR93","unstructured":"Brissaud \u00c9. Le\u00e7ons sur les maladies nerveuses. Saint-Antoine; recueillies et publi\u00e9es par Henry Meige. Legare Street Press; 1899. pp. 660."},{"key":"8076_CR94","unstructured":"Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, Abelsdorff G (Eds.). Handbuch der Neurologie. Nabu Press; 1912. pp. 506."},{"key":"8076_CR95","unstructured":"Tretiakoff C. Contribution \u00e0 l\u2019\u00e9tude de l\u2019anatomie pathologique du locus niger de Sommering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson. These med. 1919."},{"key":"8076_CR96","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/BF01485901","volume":"38","author":"H Ehringer","year":"1960","unstructured":"Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klinische Wochenschr. 1960;38:1236\u20139. https:\/\/doi.org\/10.1007\/BF01485901.","journal-title":"Klinische Wochenschr"},{"key":"8076_CR97","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1212\/WNL.13.1.56","volume":"13","author":"A Barbeau","year":"1963","unstructured":"Barbeau A, Jasmin G, Duchastel Y. Biochemistry of Parkinson\u2019s disease. Neurology. 1963;13:56\u201358. https:\/\/doi.org\/10.1212\/WNL.13.1.56.","journal-title":"Neurology"},{"key":"8076_CR98","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/ARCHNEUR.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Archives Neurol. 1969;21:343\u201354. https:\/\/doi.org\/10.1001\/ARCHNEUR.1969.00480160015001.","journal-title":"Archives Neurol"},{"key":"8076_CR99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJM197001012820107","volume":"282","author":"GC Cotzias","year":"1970","unstructured":"Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. New Engl J Med. 1970;282:31\u201333. https:\/\/doi.org\/10.1056\/NEJM197001012820107.","journal-title":"New Engl J Med"},{"key":"8076_CR100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/SCIENCE.2502843","volume":"245","author":"JW Tetrud","year":"1989","unstructured":"Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson\u2019s disease. Science (N. Y, N. Y). 1989;245:519\u201322. https:\/\/doi.org\/10.1126\/SCIENCE.2502843.","journal-title":"Science (N. Y, N. Y)"},{"key":"8076_CR101","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF00315512","volume":"45","author":"VV Myllyl\u00e4","year":"1993","unstructured":"Myllyl\u00e4 VV, Sotaniemi KA, Illi A, Suominen K, Ker\u00e4nen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson\u2019s disease. Eur J Clin Pharmacol. 1993;45:419\u201323. https:\/\/doi.org\/10.1007\/BF00315512.","journal-title":"Eur J Clin Pharmacol"},{"key":"8076_CR102","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000100803","volume":"50","author":"AL Benabid","year":"1987","unstructured":"Benabid AL, Pollak P, Louveau A, Henry S, De Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol. 1987;50:344\u20136. https:\/\/doi.org\/10.1159\/000100803.","journal-title":"Appl Neurophysiol"},{"key":"8076_CR103","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 1968;5:107\u201310. https:\/\/doi.org\/10.1016\/0014-2999(68)90164-7.","journal-title":"Eur J Pharmacol"},{"key":"8076_CR104","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/SCIENCE.6823561","volume":"219","author":"J William Langston","year":"1983","unstructured":"William Langston J, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (N. Y, N. Y). 1983;219:979\u201380. https:\/\/doi.org\/10.1126\/SCIENCE.6823561.","journal-title":"Science (N. Y, N. Y)"},{"key":"8076_CR105","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease. Nat Neurosci. 2000;3:1301\u20136. https:\/\/doi.org\/10.1038\/81834.","journal-title":"Nat Neurosci"},{"key":"8076_CR106","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ANA.410270309","volume":"27","author":"LI Golbe","year":"1990","unstructured":"Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson\u2019s disease. Annal Neurol. 1990;27:276\u201382. https:\/\/doi.org\/10.1002\/ANA.410270309.","journal-title":"Annal Neurol"},{"key":"8076_CR107","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/SCIENCE.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science (N. Y, N. Y). 1997;276:2045\u20137. https:\/\/doi.org\/10.1126\/SCIENCE.276.5321.2045.","journal-title":"Science (N. Y, N. Y)"},{"key":"8076_CR108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JPD-201981","volume":"11","author":"M Borsche","year":"2021","unstructured":"Borsche M, Pereira SL, Klein C, Gr\u00fcnewald A. Mitochondria and Parkinson\u2019s disease: clinical, molecular, and translational aspects. J Parkinson\u2019s Dis. 2021;11:45\u201360. https:\/\/doi.org\/10.3233\/JPD-201981.","journal-title":"J Parkinson\u2019s Dis"},{"key":"8076_CR109","doi-asserted-by":"publisher","unstructured":"Lizama BN, Chu CT. Neuronal autophagy and mitophagy in Parkinson\u2019s disease. Mol Aspects Med. 2021;82:100972. https:\/\/doi.org\/10.1016\/J.MAM.2021.100972.","DOI":"10.1016\/J.MAM.2021.100972"},{"key":"8076_CR110","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/JNNP.59.6.597","volume":"59","author":"PK Morrish","year":"1995","unstructured":"Morrish PK, Sawle GV. Brooks D j. Clinical and [18\u2009F] dopa PET findings in early Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1995;59:597\u2013600. https:\/\/doi.org\/10.1136\/JNNP.59.6.597.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8076_CR111","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0165-1838(94)90023-X","volume":"49","author":"S Hakusui","year":"1994","unstructured":"Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Autonomic Nerv Syst. 1994;49:81\u201384. https:\/\/doi.org\/10.1016\/0165-1838(94)90023-X.","journal-title":"J Autonomic Nerv Syst"},{"key":"8076_CR112","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1212\/WNL.45.11.1995","volume":"45","author":"D Eidelberg","year":"1995","unstructured":"Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Early differential diagnosis of Parkinson\u2019s disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1995;45:1995\u20132004. https:\/\/doi.org\/10.1212\/WNL.45.11.1995.","journal-title":"Neurology"},{"key":"8076_CR113","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/JNNP.62.2.133","volume":"62","author":"J Booij","year":"1997","unstructured":"Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AGM, et al. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson\u2019s disease. J Neurol Neurosurg psychiatry. 1997;62:133\u201340. https:\/\/doi.org\/10.1136\/JNNP.62.2.133.","journal-title":"J Neurol Neurosurg psychiatry"},{"key":"8076_CR114","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/NM1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14:504\u20136. https:\/\/doi.org\/10.1038\/NM1747.","journal-title":"Nat Med"},{"key":"8076_CR115","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/NM1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501\u20133. https:\/\/doi.org\/10.1038\/NM1746.","journal-title":"Nat Med"},{"key":"8076_CR116","doi-asserted-by":"publisher","unstructured":"Visanji NP, Brooks PL, Hazrati LN, Lang AE. The prion hypothesis in Parkinson\u2019s disease: Braak to the future. Acta Neuropathologica commun. 2013;1:2. https:\/\/doi.org\/10.1186\/2051-5960-1-2.","DOI":"10.1186\/2051-5960-1-2"},{"key":"8076_CR117","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/MDS.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov Disord. 2019;34:536. https:\/\/doi.org\/10.1002\/MDS.27646.","journal-title":"Mov Disord"},{"key":"8076_CR118","doi-asserted-by":"publisher","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commu. 2021;9:179. https:\/\/doi.org\/10.1186\/S40478-021-01282-8.","DOI":"10.1186\/S40478-021-01282-8"},{"key":"8076_CR119","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/S41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc. 2023;18:1179\u201396. https:\/\/doi.org\/10.1038\/S41596-022-00787-3.","journal-title":"Nat Protoc"},{"key":"8076_CR120","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/MDS.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, et al. Accurate detection of \u03b1-synuclein seeds in CSF from iRBD and Parkinson patients in the DeNoPa cohort. Mov Disord Off J Mov Disord Soc. 2023;38:567. https:\/\/doi.org\/10.1002\/MDS.29329.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR121","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/ANA.26089","volume":"89","author":"W Singer","year":"2021","unstructured":"Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Sletten DM, Gehrking TL, et al. Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Annals Neurol. 2021;89:1212\u201320. https:\/\/doi.org\/10.1002\/ANA.26089.","journal-title":"Annals Neurol"},{"key":"8076_CR122","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578:273\u20137. https:\/\/doi.org\/10.1038\/s41586-020-1984-7.","journal-title":"Nature"},{"key":"8076_CR123","doi-asserted-by":"crossref","unstructured":"Calne DB. Is \u2018Parkinson\u2019s disease\u2019 one disease? J Neurol Neurosurg Psychiatry. 1989;18\u201321.","DOI":"10.1136\/jnnp.52.Suppl.18"},{"key":"8076_CR124","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-7091-6360-3_5","volume":"56","author":"AD Korczyn","year":"1999","unstructured":"Korczyn AD. Parkinson\u2019s disease: one disease entity or many. J Neural Transm Suppl. 1999;56:107\u201311. https:\/\/doi.org\/10.1007\/978-3-7091-6360-3_5.","journal-title":"J Neural Transm Suppl"},{"key":"8076_CR125","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/NRN.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435\u201350. https:\/\/doi.org\/10.1038\/NRN.2017.62.","journal-title":"Nat Rev Neurosci"},{"key":"8076_CR126","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer P, Van Den Berge N. Brain-first versus gut-first parkinson\u2019s disease: a hypothesis. J Parkinson\u2019s Dis. 2019;9:S281\u201395. https:\/\/doi.org\/10.3233\/JPD-191721.","journal-title":"J Parkinson\u2019s Dis"},{"key":"8076_CR127","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1474-4422(21)00219-2","volume":"20","author":"Y Sharabi","year":"2021","unstructured":"Sharabi Y, Vatine GD, Ashkenazi A. Parkinson\u2019s disease outside the brain: targeting the autonomic nervous system. Lancet Neurol. 2021;20:868\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(21)00219-2.","journal-title":"Lancet Neurol"},{"key":"8076_CR128","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/JAMANEUROL.2013.172","volume":"70","author":"KM Doherty","year":"2013","unstructured":"Doherty KM, Silveira-Moriyama L, Parkkinen L, Healy DG, Farrell M, Mencacci NE, et al. Parkin disease: a clinicopathologic entity. JAMA Neurol. 2013;70:571\u20139. https:\/\/doi.org\/10.1001\/JAMANEUROL.2013.172.","journal-title":"JAMA Neurol"},{"key":"8076_CR129","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/MDS.29419","volume":"38","author":"TF Outeiro","year":"2023","unstructured":"Outeiro TF, Alcalay RN, Antonini A, Attems J, Bonifati V, Cardoso F, et al. Defining the riddle in order to solve it: there is more than one \u2018Parkinson\u2019s disease\u2019. Mov Disord Off J Mov Disord Soc. 2023;38:1127\u201342. https:\/\/doi.org\/10.1002\/MDS.29419.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"8076_CR130","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/MDS.29833","volume":"39","author":"AD Korczyn","year":"2024","unstructured":"Korczyn AD. Rethinking Parkinson\u2019s disease: a syndromic perspective. Mov Disord Off J Mov Disord Soc. 2024;39:1079\u201380. https:\/\/doi.org\/10.1002\/MDS.29833.","journal-title":"Mov Disord Off J Mov Disord Soc"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08076-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08076-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08076-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:11:25Z","timestamp":1762521085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08076-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8076"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08076-z","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"808"}}